metformin and Peritoneal Carcinomatosis
metformin has been researched along with Peritoneal Carcinomatosis in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Metformin-treated mice exhibited suppressed intraperitoneal tumor growth and extended survival, and these effects were lost in mice with severe combined immunodeficiency." | 1.51 | Metformin Prevents Peritoneal Dissemination ( Eguchi, S; Hirayama, T; Kanetaka, K; Kobayashi, S; Matsuo, M; Nagata, Y; Nishida, M; Udono, H; Yoneda, A, 2019) |
"Metformin treatment enhanced AMPK activation, decreasing the activity of the anabolic factors ribosomal protein S6 and p4EBP-1 and inducing mitochondrial depolarization." | 1.46 | MIF/CD74 axis is a target for novel therapies in colon carcinomatosis. ( Belfiore, A; Beznoussenko, GV; Bongarzone, I; Bozzi, F; Caccia, C; Gariboldi, M; Gloghini, A; Leo, E; Leoni, V; Manenti, G; Milione, M; Mironov, AA; Mogavero, A; Pierotti, MA; Pilotti, S; Varinelli, L; Volpi, CC, 2017) |
Research
Studies (3)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Hirayama, T | 1 |
Nagata, Y | 1 |
Nishida, M | 1 |
Matsuo, M | 1 |
Kobayashi, S | 1 |
Yoneda, A | 1 |
Kanetaka, K | 1 |
Udono, H | 1 |
Eguchi, S | 1 |
Sekino, N | 1 |
Kano, M | 1 |
Matsumoto, Y | 1 |
Sakata, H | 1 |
Murakami, K | 1 |
Toyozumi, T | 1 |
Otsuka, R | 1 |
Yokoyama, M | 1 |
Shiraishi, T | 1 |
Okada, K | 1 |
Kamata, T | 1 |
Ryuzaki, T | 1 |
Matsubara, H | 1 |
Bozzi, F | 1 |
Mogavero, A | 1 |
Varinelli, L | 1 |
Belfiore, A | 1 |
Manenti, G | 1 |
Caccia, C | 1 |
Volpi, CC | 1 |
Beznoussenko, GV | 1 |
Milione, M | 1 |
Leoni, V | 1 |
Gloghini, A | 1 |
Mironov, AA | 1 |
Leo, E | 1 |
Pilotti, S | 1 |
Pierotti, MA | 1 |
Bongarzone, I | 1 |
Gariboldi, M | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Melanoma, breAst or Lung Cancer Patients With Brain Metastases: the Phase II OPTIMAL Study[NCT04001725] | Phase 2 | 110 participants (Anticipated) | Interventional | 2019-10-15 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Other Studies
3 other studies available for metformin and Peritoneal Carcinomatosis
Article | Year |
---|---|
Metformin Prevents Peritoneal Dissemination
Topics: Animals; Biomarkers; Cell Line, Tumor; Disease Models, Animal; Humans; Immunomodulation; Immunopheno | 2019 |
The Antitumor Effects of Metformin on Gastric Cancer
Topics: Adenylate Kinase; AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Cell Line, T | 2018 |
MIF/CD74 axis is a target for novel therapies in colon carcinomatosis.
Topics: AMP-Activated Protein Kinases; Antigens, Differentiation, B-Lymphocyte; Cell Proliferation; Cell Sur | 2017 |